Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

Mes dernières consult.
Most popular
Analysis summary4-Traders Strategies

A resistance as obstacle

share with twitter share with LinkedIn share with facebook
share via e-mail
Recevoir les alertes
11/22/2013 | 04:08pm

The share is in contact with an important level. We suggest caution because this point could stop the bullish trend.

From a fundamental viewpoint, firstly, we note the high valuation of the company. The P/E ratio for the current year is at 29.18x and expected at 20.92x for next year. The EPS has also been highly revised during the last 12 month going from 2.98 to 1.67. EPS forecast for 2014 are also very pessimistic.

From a technical viewpoint, the proximity with the USD 48.75 resistance limits the upside potential on the stock. The uptrend in the short term could be stopped by this level and prices could decrease sharply in the coming sessions. Technical indicators also show an overbought situation that reinforces this bearish scenario. Thus, there is a higher downside potential than upside.

The graphical and financial configuration argues to establish a short position at the current price. Merck & Co. has all the characteristics for short selling. The first objective will be fixed near the USD 46.55, the short term support and by extension the USD 45.1 area. This strategy should be protected by a stop loss above USD 48.74.

Bastien Chabasseuil
© Zonebourse.com 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
Recevoir les alertes

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2018 42 031 M
EBIT 2018 13 523 M
Net income 2018 7 169 M
Debt 2018 15 697 M
Yield 2018 3,11%
P/E ratio 2018 24,03
P/E ratio 2019 16,61
EV / Sales 2018 4,40x
EV / Sales 2019 4,20x
Capitalization 169 B
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Duration : Period : Week
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders